| Stage | LLY | % of rev | BMY | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $24.4B | 100.00% | $13.1B | 100.00% | LLY ×1.87 |
| Gross profit | $20.5B | 83.88% | $7.4B | 56.35% | LLY +27.5pp |
| Operating income | $8.6B | 35.28% | $2.8B | 21.75% | LLY +13.5pp |
| Pre-tax income | $8.4B | 34.46% | $2.5B | 19.40% | LLY +15.1pp |
| Net income | $6.5B | 26.44% | $2.2B | 16.54% | LLY +9.9pp |
| Stage | LLY | BMY | Gap · A − B |
|---|---|---|---|
| Revenue | $24.4B100.00% | $13.1B100.00% | LLY ×1.87 |
| Gross profit | 83.88%$20.5B | 56.35%$7.4B | LLY +27.5pp |
| Operating income | 35.28%$8.6B | 21.75%$2.8B | LLY +13.5pp |
| Pre-tax income | 34.46%$8.4B | 19.40%$2.5B | LLY +15.1pp |
| Net income |
| 26.44%$6.5B |
| 16.54%$2.2B |
| LLY +9.9pp |
LLY · NKTR 10-KMar 13 '26
“In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursements from BMS, and a $150.0 million upfront payment from Eli Lilly and Company for our collaboration agreement for rezpegaldesleukin.”
BMY · NKTR 10-KMar 13 '26
“In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursements from BMS, and a $150.0 million upfront payment from Eli Lilly and Company for our collaboration agreement for rezpegaldesleukin.”
LLY · SDGR 10-KFeb 25 '26
“In September 2022, we entered into a collaboration with Lilly under which we are responsible for the discovery and optimization of small molecule compounds addressing an immunology target.”
BMY · SDGR 10-KFeb 25 '26
“We are party to an exclusive, worldwide collaboration and license agreement with BMS, pursuant to which we and BMS agreed to collaborate in the discovery, research and development of small molecule compounds for biological targets in the oncology, neurology and immunology therapeutic areas.”
LLY · VNDA 10-KFeb 12 '26
“In April 2012, we entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which we acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize NEREUS TM for all human indications.”
BMY · VNDA 10-KFeb 12 '26
“In February 2004, we entered into a license agreement with Bristol-Myers Squibb (BMS) under which we received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ ® .”